Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaozheng Sanjie decoction is a Traditional Chinese Medicine (TCM) herbal formulation developed by researchers at Dongzhimen Hospital, Beijing University of Chinese Medicine. It is primarily indicated for the treatment of diabetic kidney disease (DKD), chronic kidney disease (CKD), and renal failure. The decoction's development is rooted in the Shenluozhengjia theory, which characterizes the progression of diabetic nephropathy as the formation of pathological masses or stasis (Zhengjia) within the kidney's collateral network. By targeting these masses, the decoction aims to alleviate renal fibrosis, improve renal blood flow, and preserve kidney function. In clinical trial settings (e.g., ChiCTR-IOR-17012681), it is often evaluated as part of a comprehensive TCM regimen alongside other formulations like Tianjing Tongluo decoction to optimize prevention and treatment schemes for renal failure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiaozheng sanjie decoction.